#United States #Princeton #pharmaceuticals #FarmaMondo #Natalie Douglas

FarmaMondo Welcomes Natalie Douglas as Independent Director

In a significant move to strengthen its leadership, FarmaMondo, an international pharmaceutical commercial organization, has appointed Natalie Douglas as an independent director. This decision comes at a time when the company is striving to enhance its partnerships with pharmaceutical and biotech companies, particularly in the U.S.

A Visionary Leader in Managed Access

Natalie Douglas, known for her groundbreaking work in establishing managed access programs, has been a formidable force in the healthcare sector. With an exceptional career that includes pivotal roles, such as her time leading at Johnson & Johnson and founding IDIS, she has consistently championed the cause of increasing patient access to vital medicines across the globe.

Under her guidance, IDIS became the world's foremost provider of managed access programs, launching over 200 programs for 40 pharmaceutical and biotech firms. Douglas’s work has been instrumental in demonstrating the potential of these programs to transform patient access to necessary treatments, particularly for severe and rare diseases. Her innovative approach and emphasis on ethical, systematic, and large-scale access have set a standard within the industry, making her an ideal addition to the FarmaMondo board.

FarmaMondo's Commitment to Global Patient Access

FarmaMondo operates in more than 50 emerging markets, aiming to ensure that patients have timely access to critical therapies. By employing an integrated approach to early market access and commercialization, the organization serves as a vital link between pharmaceutical companies and patients who would otherwise be deprived of these treatments.

With 14 regional subsidiaries and a portfolio boasting over 50 therapies, which include options for oncology, hematology, endocrinology, neurology, and metabolic diseases, FarmaMondo is well-positioned to scale its operations significantly. The appointment of Douglas comes at a crucial juncture; her extensive experience and leadership in patient access can significantly impact the U.S. market, aligning perfectly with the company’s mission.

Comments from Leadership

Yaron Spigel, CEO of FarmaMondo, expressed enthusiasm about Douglas's appointment, stating, “Natalie Douglas is a major figure in global patient access to pharmaceuticals. Her establishment of the managed access program standard has bridged the gap between pharmaceutical companies and healthcare providers, especially in challenging markets. Her joining us is pivotal as we expand our partnerships to address the global needs of patients.”

Douglas herself remarked on her new role, saying, “It’s a privilege to bring my global access expertise to FarmaMondo and help drive its U.S. market expansion. I am inspired by the work Yaron and his team are doing to shape a future model for drug access in international markets. FarmaMondo’s efforts resonate with my commitment to aid patients in urgent need of impactful drugs, especially those residing beyond traditional market boundaries.”

Conclusion

As FarmaMondo forges ahead on its trajectory of growth, particularly in the U.S., securing Natalie Douglas on its board serves as a strategic enhancement of its mission to increase patient access to groundbreaking therapies. Her appointment not only highlights the company's commitment to innovative healthcare solutions but also positions FarmaMondo to be a leader in addressing the complexities of global pharmaceutical access. The future looks promising as they continue to pioneer pathways for patients worldwide, ensuring they receive the treatments they need when they need them.